Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 332,261
  • Shares Outstanding, K 87,437
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -37,450 K
  • EBIT $ -99 M
  • EBITDA $ -98 M
  • 60-Month Beta 0.42
  • Price/Sales 111.13
  • Price/Cash Flow N/A
  • Price/Book 1.33

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 102.46%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 733.99% on 04/28/25
  • IV Low 0.00% on 12/02/25
  • Expected Move (DTE 41) 0.04 (1.35%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 2,040
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 16,830
  • Open Int (30-Day) 211,967
  • Expected Range 3.10 to 3.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.34
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.56
  • Prior Year -6.01
  • Growth Rate Est. (year over year) +94.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +30.49%
on 12/03/25
4.07 -2.21%
on 12/05/25
+0.43 (+12.11%)
since 11/05/25
3-Month
2.80 +42.14%
on 10/15/25
4.54 -12.33%
on 10/24/25
+0.48 (+13.71%)
since 09/05/25
52-Week
1.35 +194.81%
on 08/11/25
26.83 -85.17%
on 12/31/24
-7.69 (-65.90%)
since 12/05/24

Most Recent Stories

More News
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals: Q3 Earnings Snapshot

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced...

XFOR : 3.98 (+4.74%)
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide 

Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful...

XFOR : 3.98 (+4.74%)
ALT : 5.24 (-1.32%)
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals  (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private...

XFOR : 3.98 (+4.74%)
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman,...

XFOR : 3.98 (+4.74%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 4.43
2nd Resistance Point 4.25
1st Resistance Point 4.12
Last Price 3.98
1st Support Level 3.80
2nd Support Level 3.62
3rd Support Level 3.48

See More

52-Week High 26.83
Fibonacci 61.8% 17.10
Fibonacci 50% 14.09
Fibonacci 38.2% 11.08
Last Price 3.98
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar